The first part of the session titled Innovation in Transition: Models, Global Trends, Regulatory Challenges, and Funding Opportunities started with a presentation from John B. Simpson, MD, PhD, chief executive officer at Avinger, Inc, called Individual-Based Innovation. Dr Simpson briefly described the lumivascular approach to treatment of cardiovascular disease, which is image-guided atherectomy.
The first part of the session titled “Innovation in Transition: Models, Global Trends, Regulatory Challenges, and Funding Opportunities” started with a presentation from John B. Simpson, MD, PhD, chief executive officer at Avinger, Inc, called “Individual-Based Innovation.” Dr Simpson briefly described the lumivascular approach to treatment of cardiovascular disease, which is image-guided atherectomy. This technology combines imaging and therapy in a single device without radiation exposure to the patient.
Next, “University-Based Technology Transfer” was presented by Karin Immergluck, PhD, associate director and acting director of technology management at the University of California San Francisco Office of Innovation. Because it is becoming more difficult for researchers to get funding, especially for translational type projects, UCSF has created an office that promotes development alliances between the university and industry for joint drug discovery and clinical development.
Hanson S. Gifford, BSME, of The Foundry, LLC, presented “Incubators and Accelerators.” Although the term “incubator” can mean many things, in this talk it represented a serial entrepreneurial approach to device development. According to the presentation, the Foundry team, which has dozens of ongoing studies and over 300 patents pending, has become successful due to alignment of interests and sustained funding, in addition to efficiency, persistence, and creativity.
In “Corporate Partnerships or Development,” Mike Buck, vice president of global market development at Abbott Vascular, indicated that his company is embracing a more open innovation model focused on increased partnership. Companies are no longer solely relying on internal R&D but are developing external, corporate partnership considerations. This approach was successful for Abbott in its pursuit of bioabsorbable vascular solutions.
The keynote lecture, “Emerging Regulatory and Financial Changes: Impact on Global Medical Device Innovation,” was given by Jack L. Lewin, MD, president and CEO of Cardiovascular Research Foundation in Washington, DC. Dr Lewin described barriers to cardiovascular device innovation, including growing regulatory burdens, limitations of small businesses as device start-ups, the proposed ACA device tax, and new payment reform models, which may disincentivize innovation. According to Dr Lewin, device innovation depends on the dynamics of the following: acceleration of scientific discovery, advancement of engineering, rapid progress in information exchange and analytics, and payment and delivery system reforms. He also discussed rethinking the global regulatory enterprise. Overall, he remains optimistic about device innovation, saying, “It’s a fantastic time to be in healthcare, and in particular, cardiovascular medicine.”
The next presentation was “The Compelling Case for Innovation in Emerging Markets and Reverse Innovation,” by Peter J. Fitzgerald, MD, PhD, professor of medicine & engineering at Stanford University Medical Center. After discussing factors that currently impede innovation—regulation, legislation, and litigation—Dr Fitzgerald reviewed ongoing innovations in Israel, Taiwan, and
China. He believes that the United States will again lead the way in healthcare advancements in the future, and efforts will focus on prevention and improving healthcare delivery.
In “Emerging Funding Models and Partnerships: Fueling the Innovation Engine,” Casey McGlynn, JD, with Wilson Sonsini Goodrich & Rosati, discussed a new model of funding for innovative processes. Because there is a lack of venture capital available to medical technology today, this new model is necessary. The “early exit” model involves selling prior to commercialization and partnering with existing organizations (often large universities or incubators) to eliminate or reduce dependence on venture capital. According to Mr McGlynn, this is a very viable model today and it allows for more control by the entrepreneur.
The final portion of this session, “New FDA Innovation Pathways: Returning Early Stage Device Development to the United States,” was presented by Andrew Farb, MD, medical officer at the US Food and Drug Administration (FDA). According to Dr Farb, the FDA’s goals are to provide early patient access to devices and regain US leadership in innovation. This involves a culture change to focus on “promoting public health, not only protecting it.” Changes include a focus on risk:benefit principle application throughout the regulatory decision, early feasibility studies, and “just-in-time” testing.
Enhancing Outpatient Hemophilia Care May Improve Health Outcomes and Costs
May 18th 2024Prospective data from patients attending a rural practice in West Virginia between 2016 and 2023 show that a quality improvement program that followed guideline recommendations and was tailored to specific patient needs reduced preventable bleeds and lowered costs.
Read More
Health Equity and Access Weekly Roundup: May 18, 2024
May 18th 2024The US Senate hosted a panel addressing physician and health care shortages and efforts to increase minority representation in the medical field. An expert discussed initiatives to prevent senior homelessness. Advocates called for the repeal of the Comstock Act. Regulatory reforms are called for to improve rural cancer patients' access to pharmacies. Research reveals the impact of denials on patient access to immunology treatments.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
Congress Urged to Repeal Comstock Act Threatening Reproductive Rights and Public Health
May 16th 2024In a joint letter addressed to Congress, Healthcare Across Borders, Take Back the Court Action Fund, and UltraViolet Action called out the resurgence of the Comstock Act, urging immediate action to repeal this century-old law that threatens reproductive rights and public health in the US.
Read More